It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The TAR DNA Binding Protein 43 (TDP-43) has been implicated in the pathogenesis of human neurodegenerative diseases and exhibits hallmark neuropathology in amyotrophic lateral sclerosis (ALS). Here, we explore its tractability as a plasma biomarker of disease and describe its localization and possible functions in the cytosol of platelets. Novel TDP-43 immunoassays were developed on three different technical platforms and qualified for specificity, signal-to-noise ratio, detection range, variation, spike recovery and dilution linearity in human plasma samples. Surprisingly, implementation of these assays demonstrated that biobank-archived plasma samples yielded considerable heterogeneity in TDP-43 levels. Importantly, subsequent investigation attributed these differences to variable platelet recovery. Fractionations of fresh blood revealed that ≥ 95% of the TDP-43 in platelet-containing plasma was compartmentalized within the platelet cytosol. We reasoned that this highly concentrated source of TDP-43 comprised an interesting substrate for biochemical analyses. Additional characterization of platelets revealed the presence of the disease-associated phosphoserine 409/410 TDP-43 proteoform and many neuron- and astrocyte-expressed TDP-43 mRNA targets. Considering these striking similarities, we propose that TDP-43 may serve analogous functional roles in platelets and synapses, and that the study of platelet TDP-43 might provide a window into disease-related TDP-43 dyshomeostasis in the central nervous system.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 AC Immune, SA (ACIU), Lausanne, Switzerland (GRID:grid.476060.3) (ISNI:0000 0004 7702 9629)
2 International Centre for Genetic Engineering and Biotechnology, Trieste, Italy (GRID:grid.425196.d) (ISNI:0000 0004 1759 4810)
3 Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts Alzheimer’s Disease Research Center (ADRC), Charlestown, USA (GRID:grid.32224.35); MassGeneral Institute for Neurodegenerative Disease, Charlestown, USA (GRID:grid.32224.35); Eisai US, Cambridge, USA (GRID:grid.418767.b) (ISNI:0000 0004 0599 8842)
4 Sean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
5 Barrow Neurological Institute, Department of Translational Neuroscience, Phoenix, USA (GRID:grid.427785.b) (ISNI:0000 0001 0664 3531)
6 Kansas City University, Kansas City, USA (GRID:grid.258405.e) (ISNI:0000 0004 0539 5056)
7 Kansas City University, Kansas City, USA (GRID:grid.258405.e) (ISNI:0000 0004 0539 5056); Boehringer Ingelheim Vetmedica, St Joseph, USA (GRID:grid.418412.a) (ISNI:0000 0001 1312 9717)
8 Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts Alzheimer’s Disease Research Center (ADRC), Charlestown, USA (GRID:grid.32224.35)
9 Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Dipartimento di Medicina Trasfusionale Giuliano-Isontina, Trieste, Italy (GRID:grid.32224.35)
10 Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Sean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Neurological Clinical Research Institute, Boston, USA (GRID:grid.32224.35)
11 Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts Alzheimer’s Disease Research Center (ADRC), Charlestown, USA (GRID:grid.32224.35); MassGeneral Institute for Neurodegenerative Disease, Charlestown, USA (GRID:grid.32224.35); Sean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
12 Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts Alzheimer’s Disease Research Center (ADRC), Charlestown, USA (GRID:grid.32224.35); University of Oxford, Department of Physiology, Anatomy and Genetics and Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
13 Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); MassGeneral Institute for Neurodegenerative Disease, Charlestown, USA (GRID:grid.32224.35); Sean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)